MoonLake Immunotherapeutics (MLTX) Short Interest Ratio & Short Volume → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free MLTX Stock Alerts $40.77 -0.94 (-2.25%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media MoonLake Immunotherapeutics Short Interest DataCurrent Short Volume6,930,000 sharesPrevious Short Volume7,260,000 sharesChange Vs. Previous Month-4.55%Dollar Volume Sold Short$283.51 millionShort Interest Ratio / Days to Cover15.0Last Record DateApril 30, 2024Outstanding Shares63,890,000 sharesFloat Size49,500,000 sharesShort Percent of Float14.00%Today's Trading Volume179,442 sharesAverage Trading Volume306,798 sharesToday's Volume Vs. Average58% Short Selling MoonLake Immunotherapeutics ? Sign up to receive the latest short interest report for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMLTX Short Interest Over TimeMLTX Days to Cover Over TimeMLTX Percentage of Float Shorted Over Time Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 MoonLake Immunotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20246,930,000 shares $283.51 million -4.6%14.0%15 $40.91 4/15/20247,260,000 shares $316.83 million -5.1%15.4%15.4 $43.64 3/31/20247,650,000 shares $384.26 million +9.3%16.2%15.9 $50.23 3/15/20247,000,000 shares $330.75 million +0.9%14.8%14.8 $47.25 2/29/20246,940,000 shares $334.79 million +5.0%14.7%14.5 $48.24 2/15/20246,610,000 shares $396.80 million -0.9%14.1%13.3 $60.03 Get the Latest News and Ratings for MLTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20246,670,000 shares $372.72 million -3.2%14.5%12.2 $55.88 1/15/20246,890,000 shares $401.69 million -0.3%15.0%10.4 $58.30 12/31/20236,910,000 shares $417.29 million -8.0%15.0%9.6 $60.39 12/15/20237,510,000 shares $455.48 million -4.1%16.3%10.4 $60.65 11/30/20237,830,000 shares $343.82 million +7.0%17.7%10.9 $43.91 11/15/20237,320,000 shares $287.38 million +10.2%16.6%10.6 $39.26 10/31/20236,640,000 shares $344.02 million -6.4%16.7%10.4 $51.81 10/15/20237,090,000 shares $387.61 million +3.5%19.7%13.8 $54.67 9/30/20236,850,000 shares $390.45 million +4.1%19.0%14.1 $57.00 9/15/20236,580,000 shares $369.93 million -1.2%15.6%8.7 $56.22 8/31/20236,660,000 shares $383.42 million -10.1%16.8%9.1 $57.57 8/15/20237,410,000 shares $417.03 million +10.6%18.7%10.1 $56.28 7/31/20236,700,000 shares $407.43 million +1.8%16.8%9.2 $60.81 7/15/20236,580,000 shares $357.10 million +6.8%15.2%8.9 $54.27 6/30/20236,160,000 shares $314.16 million +33.9%17.2%8.8 $51.00 6/15/20234,600,000 shares $125.12 million +12.5%13.9%8.5 $27.20 5/31/20234,090,000 shares $111.29 million -5.3%12.8%10.5 $27.21 5/15/20234,320,000 shares $115.60 million +30.1%13.6%12.2 $26.76 4/30/20233,320,000 shares $70.72 million +78.5%12.0%11 $21.30 4/15/20231,860,000 shares $35.41 million +0.5%6.7%6.9 $19.04 3/31/20231,850,000 shares $39.57 million +119.4%6.5%9.1 $21.39 3/15/2023843,300 shares $17.13 million -4.5%2.7%4.7 $20.31 2/28/2023883,400 shares $16.95 million +44.4%2.8%6.9 $19.19 2/15/2023611,800 shares $10.27 million -0.1%1.9%6 $16.79 1/31/2023612,600 shares $7.32 million -0.8%1.9%7.6 $11.95 1/15/2023617,300 shares $7.34 million +0.7%1.9%8.8 $11.89 12/30/2022612,800 shares $6.43 million -14.7%1.9%10.1 $10.50 12/15/2022718,100 shares $6.75 million -15.1%2.3%12.5 $9.40 11/30/2022845,400 shares $8.39 million +38.1%2.7%18.9 $9.93 11/15/2022612,200 shares $5.48 million +0.8%2.0%14.5 $8.95 10/31/2022607,100 shares $5.00 million +1.0%2.0%13.3 $8.24 10/15/2022601,400 shares $5.29 million +0.7%2.0%11 $8.80 9/30/2022597,000 shares $4.63 million +2.5%2.0%10.3 $7.76 9/15/2022582,300 shares $4.48 million +1.5%2.0%11.7 $7.69Trump’s Former Wingman Bets Big on AI (Ad)One of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. MLTX Short Interest - Frequently Asked Questions What is MoonLake Immunotherapeutics' current short interest? Short interest is the volume of MoonLake Immunotherapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 6,930,000 shares of MLTX short. 14.00% of MoonLake Immunotherapeutics' shares are currently sold short. Learn More on MoonLake Immunotherapeutics' current short interest. What is a good short interest ratio for MoonLake Immunotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MLTX shares currently have a short interest ratio of 15.0. Learn More on MoonLake Immunotherapeutics's short interest ratio. What is a good short interest percentage for MoonLake Immunotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.00% of MoonLake Immunotherapeutics' floating shares are currently sold short. Is MoonLake Immunotherapeutics' short interest increasing or decreasing? MoonLake Immunotherapeutics saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,930,000 shares, a decrease of 4.5% from the previous total of 7,260,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MoonLake Immunotherapeutics' float size? MoonLake Immunotherapeutics currently has issued a total of 63,890,000 shares. Some of MoonLake Immunotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MoonLake Immunotherapeutics currently has a public float of 49,500,000 shares. How does MoonLake Immunotherapeutics' short interest compare to its competitors? 14.00% of MoonLake Immunotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to MoonLake Immunotherapeutics: Bausch Health Companies Inc. (5.73%), Merus (5.76%), Maravai LifeSciences Holdings, Inc. (6.66%), Janux Therapeutics, Inc. (9.55%), Rhythm Pharmaceuticals, Inc. (17.37%), Dyne Therapeutics, Inc. (18.91%), ACADIA Pharmaceuticals Inc. (7.28%), Amicus Therapeutics, Inc. (9.71%), Avidity Biosciences, Inc. (11.91%), MorphoSys AG (0.83%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short MoonLake Immunotherapeutics stock? Short selling MLTX is an investing strategy that aims to generate trading profit from MoonLake Immunotherapeutics as its price is falling. MLTX shares are trading down $0.94 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MoonLake Immunotherapeutics? A short squeeze for MoonLake Immunotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MLTX, which in turn drives the price of the stock up even further. How often is MoonLake Immunotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MLTX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Bausch Health Companies Short Interest Data Merus Short Interest Data Maravai LifeSciences Short Interest Data Janux Therapeutics Short Interest Data Rhythm Pharmaceuticals Short Interest Data Dyne Therapeutics Short Interest Data ACADIA Pharmaceuticals Short Interest Data Amicus Therapeutics Short Interest Data Avidity Biosciences Short Interest Data MorphoSys Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MLTX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith